Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Olema Pharmaceuticals, Inc is a biotechnology business based in the US. Olema Pharmaceuticals shares (OLMA) are listed on the NASDAQ and all prices are listed in US Dollars. Olema Pharmaceuticals employs 36 staff and has a market cap (total outstanding shares value) of USD0.00.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Active traders
52-week range | USD$26.74 - USD$60.27 |
---|---|
50-day moving average | USD$37.7387 |
200-day moving average | USD$43.1365 |
Wall St. target price | USD$65 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | N/A |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -7.85% |
Return on equity TTM | -13.13% |
Profit margin | 0% |
Book value | N/A |
Market capitalisation | USD$1.4 billion |
TTM: trailing 12 months
There are currently 860,988 Olema Pharmaceuticals shares held short by investors – that's known as Olema Pharmaceuticals's "short interest". This figure is 94.9% up from 441,853 last month.
There are a few different ways that this level of interest in shorting Olema Pharmaceuticals shares can be evaluated.
Olema Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Olema Pharmaceuticals shares currently shorted divided by the average quantity of Olema Pharmaceuticals shares traded daily (recently around 257011.34328358). Olema Pharmaceuticals's SIR currently stands at 3.35. In other words for every 100,000 Olema Pharmaceuticals shares traded daily on the market, roughly 3350 shares are currently held short.
To gain some more context, you can compare Olema Pharmaceuticals's short interest ratio against those of similar companies.
However Olema Pharmaceuticals's short interest can also be evaluated against the total number of Olema Pharmaceuticals shares, or, against the total number of tradable Olema Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Olema Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Olema Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0324% of the tradable shares (for every 100,000 tradable Olema Pharmaceuticals shares, roughly 32 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Olema Pharmaceuticals.
Find out more about how you can short Olema Pharmaceuticals stock.
We're not expecting Olema Pharmaceuticals to pay a dividend over the next 12 months.
Olema Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.